中性粒细胞与淋巴细胞比值优于血小板与淋巴细胞比值，可作为一线铂类化疗治疗晚期非小细胞肺癌的预后预测指标。
Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
机构信息
Weifang Medical University, Weifang, PR China.
Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, PR China.
出版信息
Future Oncol. 2019 Feb;15(6):625-635. doi: 10.2217/fon-2018-0667. Epub 2018 Nov 15.
AIM
We aimed to investigate the prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy and determine which of the two was a better predictor of prognosis.
MATERIALS & METHODS: We conducted multivariate Cox regression analysis to assess the independent effects of the NLR and PLR on patient survival.
RESULTS
In multivariate Cox regression analysis, the NLR was an independent risk factor predicting poor prognostic factor (HR: 2.464; 95% CI: 1.305-4.652; p = 0.005) and overall survival (HR: 1.954; 95% CI: 1.172-3.257; p = 0.01); however, the PLR was not a prognostic factor (progression-free survival; p = 0.105; overall survival; p = 0.239).
CONCLUSION
The NLR was a better prognostic indicator than the PLR for advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
目的
本研究旨在探讨中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）对一线铂类化疗治疗晚期非小细胞肺癌患者的预后影响，并确定哪一种比值是更好的预后预测指标。
材料与方法
我们进行了多变量 Cox 回归分析，以评估 NLR 和 PLR 对患者生存的独立影响。
结果
多变量 Cox 回归分析显示，NLR 是预测不良预后因素的独立危险因素（HR：2.464；95%CI：1.305-4.652；p = 0.005）和总生存期（HR：1.954；95%CI：1.172-3.257；p = 0.01）的独立危险因素；然而，PLR 不是预后因素（无进展生存期；p = 0.105；总生存期；p = 0.239）。
结论
对于一线铂类化疗治疗的晚期非小细胞肺癌患者，NLR 是比 PLR 更好的预后指标。
Zotero 插件